277 related articles for article (PubMed ID: 25794019)
1. Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease.
Trinh T; Haridas AS; Sullivan TJ
Ophthalmic Plast Reconstr Surg; 2016; 32(6):e128-e129. PubMed ID: 25794019
[TBL] [Abstract][Full Text] [Related]
2. Graves' disease after treatment with alemtuzumab for multiple sclerosis.
Tsourdi E; Gruber M; Rauner M; Blankenburg J; Ziemssen T; Hofbauer LC
Hormones (Athens); 2015; 14(1):148-53. PubMed ID: 25402383
[TBL] [Abstract][Full Text] [Related]
3. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series.
Roos JCP; Moran C; Chatterjee VK; Jones J; Coles A; Murthy R
Eye (Lond); 2019 Feb; 33(2):223-229. PubMed ID: 30498266
[TBL] [Abstract][Full Text] [Related]
4. Onset of Marine-Lenhart syndrome and Graves' ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis.
Le Moli R; Russo M; Malandrino P; Vella V; Belfiore A; Frasca F
Hormones (Athens); 2021 Mar; 20(1):161-165. PubMed ID: 32500462
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review.
Aranha AA; Amer S; Reda ES; Broadley SA; Davoren PM
Endocr Pract; 2013; 19(5):821-8. PubMed ID: 23757618
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management.
Mahzari M; Arnaout A; Freedman MS
Can J Neurol Sci; 2015 Sep; 42(5):284-91. PubMed ID: 25990097
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab.
Muller I; Maioli S; Armenti M; Porcaro L; Currò N; Iofrida E; Pignataro L; Manso J; Mian C; Geginat J; Salvi M
Eur Thyroid J; 2024 Apr; 13(2):. PubMed ID: 38471303
[TBL] [Abstract][Full Text] [Related]
8. A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy.
Park ESY; Rabinowits G; Hamnvik OR; Dagi LR
J AAPOS; 2018 Aug; 22(4):310-312. PubMed ID: 29626663
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
[TBL] [Abstract][Full Text] [Related]
11. Drug safety evaluation of alemtuzumab for multiple sclerosis.
Willis M; Robertson NP
Expert Opin Drug Saf; 2014 Aug; 13(8):1115-24. PubMed ID: 24935240
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
Alamo A; Condorelli RA; La Vignera S; Calogero AE
Int J Immunopathol Pharmacol; 2019; 33():2058738419843690. PubMed ID: 30968726
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
Walsh M; Chaudhry A; Jayne D
Ann Rheum Dis; 2008 Sep; 67(9):1322-7. PubMed ID: 18055469
[TBL] [Abstract][Full Text] [Related]
14. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab treatment of multiple sclerosis.
Coles AJ
Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
[TBL] [Abstract][Full Text] [Related]
16. Graves' disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis.
Duarte DB; Silva AMD; Freitas C; Cardoso H
Endocr Regul; 2021 Sep; 55(3):169-173. PubMed ID: 34523298
[No Abstract] [Full Text] [Related]
17. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
18. [Alemtuzumab-induced Graves' disease].
Sheremeta MS; Korchagina MO; Guseinova RM; Schmidt TE; Nizhegorodova KS; Sviridenko NY; Melnichenko GA
Probl Endokrinol (Mosk); 2023 Jun; 69(3):51-57. PubMed ID: 37448247
[TBL] [Abstract][Full Text] [Related]
19. The outlook for alemtuzumab in multiple sclerosis.
Williams T; Coles A; Azzopardi L
BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
[TBL] [Abstract][Full Text] [Related]
20. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]